[
  {
    "ts": null,
    "headline": "3 Healthcare Stocks That Are Screaming Deals Right Now",
    "summary": "These bargains could prove good for your financial health.",
    "url": "https://finnhub.io/api/news?id=8bf23576e2eca03c53bc15bfc696179620f6836a342df7be36797215243e3c57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761510180,
      "headline": "3 Healthcare Stocks That Are Screaming Deals Right Now",
      "id": 137216288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These bargains could prove good for your financial health.",
      "url": "https://finnhub.io/api/news?id=8bf23576e2eca03c53bc15bfc696179620f6836a342df7be36797215243e3c57"
    }
  },
  {
    "ts": null,
    "headline": "Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data",
    "summary": "Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential. On October 20, Lake Street analyst Thomas Flaten raised the firm’s price target on Evaxion Biotech to $11 from $6 and kept a Buy rating on the shares. This sentiment was announced after the company announced two-year Phase 2 data for […]",
    "url": "https://finnhub.io/api/news?id=41dc9889695183c06d2620b736f2f5d02b531942b2c530b1ea6126c13235fb1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761473156,
      "headline": "Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data",
      "id": 137216289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential. On October 20, Lake Street analyst Thomas Flaten raised the firm’s price target on Evaxion Biotech to $11 from $6 and kept a Buy rating on the shares. This sentiment was announced after the company announced two-year Phase 2 data for […]",
      "url": "https://finnhub.io/api/news?id=41dc9889695183c06d2620b736f2f5d02b531942b2c530b1ea6126c13235fb1a"
    }
  }
]